Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Ity Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen, 6525 GA, The Netherlands Full list of author information is available at the end of the articleof breast cancers. Apart from breast epithelial tumor cells, ESR2 is also expressed in adjacent infiltrating lymphocytes, fibroblasts, and endothelial cells, all of which are known to influence tumor growth [3]. However, its precise role in bre
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
The Reporting Recommendations for Tumor Marker Prognostic Studies guidelines [11]. The primary breast tumors were from patients with detailed clinical follow-up as previously described [12-14]. ER protein status was determined by routine ligand-binding assays or enzyme immunoassays [15], and ESR1, ESR2, and PGR mRNA status wasTissue processing, RNA isolation, cDNA synthesis, and quantitative RT-PC
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
Was fitted. The Cox proportional hazards assumptions were checked and the analyses were stratified by tumor size and ESR1 to meet the proportional hazards assumption. In a second block, the contributions of DC-SCRIPT and ESR2 (as continuous or dichotomized variables) were investigated. bWith quantitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, re